vs

Side-by-side financial comparison of NELNET INC (NNI) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $33.5M, roughly 1.1× NELNET INC). NELNET INC runs the higher net margin — 172.3% vs -304.2%, a 476.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 79.6%). NELNET INC produced more free cash flow last quarter ($396.7M vs $-47.3M). Over the past eight quarters, NELNET INC's revenue compounded faster (62.0% CAGR vs 60.5%).

Nelnet, Inc. is a United States–based conglomerate that primarily focuses on financial services including student and consumer loan origination and servicing. Additionally, the company operates an investing arm, an internet bank and has a 26% stake in Allo Fiber, a cable and internet provider. The company is headquartered in Lincoln, Nebraska.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

NNI vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.1× larger
RXRX
$35.5M
$33.5M
NNI
Growing faster (revenue YoY)
RXRX
RXRX
+602.1% gap
RXRX
681.7%
79.6%
NNI
Higher net margin
NNI
NNI
476.5% more per $
NNI
172.3%
-304.2%
RXRX
More free cash flow
NNI
NNI
$444.1M more FCF
NNI
$396.7M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
NNI
NNI
Annualised
NNI
62.0%
60.5%
RXRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NNI
NNI
RXRX
RXRX
Revenue
$33.5M
$35.5M
Net Profit
$57.8M
$-108.1M
Gross Margin
50.5%
59.8%
Operating Margin
-304.8%
Net Margin
172.3%
-304.2%
Revenue YoY
79.6%
681.7%
Net Profit YoY
-8.5%
39.6%
EPS (diluted)
$1.62
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NNI
NNI
RXRX
RXRX
Q4 25
$33.5M
$35.5M
Q3 25
$23.2M
$5.2M
Q2 25
$26.1M
$19.2M
Q1 25
$24.7M
$14.7M
Q4 24
$18.7M
$4.5M
Q3 24
$16.6M
$26.1M
Q2 24
$14.9M
$14.4M
Q1 24
$12.8M
$13.8M
Net Profit
NNI
NNI
RXRX
RXRX
Q4 25
$57.8M
$-108.1M
Q3 25
$106.7M
$-162.3M
Q2 25
$181.5M
$-171.9M
Q1 25
$82.6M
$-202.5M
Q4 24
$63.2M
$-178.9M
Q3 24
$2.4M
$-95.8M
Q2 24
$45.1M
$-97.5M
Q1 24
$73.4M
$-91.4M
Gross Margin
NNI
NNI
RXRX
RXRX
Q4 25
50.5%
59.8%
Q3 25
29.6%
-183.8%
Q2 25
29.8%
-4.9%
Q1 25
30.5%
-48.0%
Q4 24
13.7%
-181.4%
Q3 24
0.1%
53.7%
Q2 24
27.3%
36.2%
Q1 24
15.3%
19.1%
Operating Margin
NNI
NNI
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-916.8%
Q1 25
-1297.9%
Q4 24
97.7%
-4042.4%
Q3 24
-13.4%
-377.1%
Q2 24
88.0%
-697.4%
Q1 24
-698.4%
Net Margin
NNI
NNI
RXRX
RXRX
Q4 25
172.3%
-304.2%
Q3 25
460.5%
-3135.3%
Q2 25
694.9%
-894.2%
Q1 25
334.4%
-1373.3%
Q4 24
338.2%
-3935.5%
Q3 24
14.4%
-367.5%
Q2 24
303.6%
-676.6%
Q1 24
574.4%
-662.4%
EPS (diluted)
NNI
NNI
RXRX
RXRX
Q4 25
$1.62
$-0.17
Q3 25
$2.94
$-0.36
Q2 25
$4.97
$-0.41
Q1 25
$2.26
$-0.50
Q4 24
$1.74
$-0.56
Q3 24
$0.07
$-0.34
Q2 24
$1.23
$-0.40
Q1 24
$1.98
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NNI
NNI
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$296.0M
$743.3M
Total DebtLower is stronger
$7.8B
$9.6M
Stockholders' EquityBook value
$3.7B
$1.1B
Total Assets
$14.1B
$1.5B
Debt / EquityLower = less leverage
2.11×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NNI
NNI
RXRX
RXRX
Q4 25
$296.0M
$743.3M
Q3 25
$216.4M
$659.8M
Q2 25
$225.8M
$525.1M
Q1 25
$220.5M
$500.5M
Q4 24
$194.5M
$594.4M
Q3 24
$219.7M
$427.6M
Q2 24
$145.5M
$474.3M
Q1 24
$179.7M
$296.3M
Total Debt
NNI
NNI
RXRX
RXRX
Q4 25
$7.8B
$9.6M
Q3 25
$7.8B
$11.9M
Q2 25
$7.9B
$14.2M
Q1 25
$8.7B
$16.4M
Q4 24
$8.3B
$19.0M
Q3 24
$8.9B
$20.5M
Q2 24
$9.6B
$22.9M
Q1 24
$10.6B
Stockholders' Equity
NNI
NNI
RXRX
RXRX
Q4 25
$3.7B
$1.1B
Q3 25
$3.7B
$1.0B
Q2 25
$3.6B
$919.1M
Q1 25
$3.4B
$933.9M
Q4 24
$3.3B
$1.0B
Q3 24
$3.3B
$524.6M
Q2 24
$3.3B
$584.4M
Q1 24
$3.3B
$401.2M
Total Assets
NNI
NNI
RXRX
RXRX
Q4 25
$14.1B
$1.5B
Q3 25
$13.9B
$1.4B
Q2 25
$13.7B
$1.3B
Q1 25
$14.2B
$1.3B
Q4 24
$13.8B
$1.4B
Q3 24
$14.1B
$726.5M
Q2 24
$14.5B
$775.9M
Q1 24
$15.4B
$557.8M
Debt / Equity
NNI
NNI
RXRX
RXRX
Q4 25
2.11×
0.01×
Q3 25
2.14×
0.01×
Q2 25
2.21×
0.02×
Q1 25
2.53×
0.02×
Q4 24
2.48×
0.02×
Q3 24
2.72×
0.04×
Q2 24
2.90×
0.04×
Q1 24
3.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NNI
NNI
RXRX
RXRX
Operating Cash FlowLast quarter
$423.0M
$-46.1M
Free Cash FlowOCF − Capex
$396.7M
$-47.3M
FCF MarginFCF / Revenue
1183.0%
-133.1%
Capex IntensityCapex / Revenue
78.2%
3.5%
Cash ConversionOCF / Net Profit
7.32×
TTM Free Cash FlowTrailing 4 quarters
$663.4M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NNI
NNI
RXRX
RXRX
Q4 25
$423.0M
$-46.1M
Q3 25
$112.4M
$-117.4M
Q2 25
$81.8M
$-76.4M
Q1 25
$91.2M
$-132.0M
Q4 24
$662.9M
$-115.4M
Q3 24
$137.0M
$-59.2M
Q2 24
$133.8M
$-82.2M
Q1 24
$211.6M
$-102.3M
Free Cash Flow
NNI
NNI
RXRX
RXRX
Q4 25
$396.7M
$-47.3M
Q3 25
$100.8M
$-117.6M
Q2 25
$78.1M
$-79.6M
Q1 25
$87.8M
$-133.8M
Q4 24
$642.0M
$-116.7M
Q3 24
$132.6M
$-63.8M
Q2 24
$123.1M
$-83.4M
Q1 24
$188.3M
$-109.0M
FCF Margin
NNI
NNI
RXRX
RXRX
Q4 25
1183.0%
-133.1%
Q3 25
435.0%
-2272.5%
Q2 25
299.0%
-413.9%
Q1 25
355.6%
-907.4%
Q4 24
3438.0%
-2567.7%
Q3 24
797.9%
-244.6%
Q2 24
829.2%
-578.5%
Q1 24
1473.7%
-789.9%
Capex Intensity
NNI
NNI
RXRX
RXRX
Q4 25
78.2%
3.5%
Q3 25
50.4%
4.7%
Q2 25
14.2%
16.4%
Q1 25
13.7%
12.4%
Q4 24
111.9%
28.6%
Q3 24
26.7%
17.5%
Q2 24
71.5%
8.2%
Q1 24
181.7%
48.2%
Cash Conversion
NNI
NNI
RXRX
RXRX
Q4 25
7.32×
Q3 25
1.05×
Q2 25
0.45×
Q1 25
1.10×
Q4 24
10.50×
Q3 24
57.39×
Q2 24
2.97×
Q1 24
2.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons